235 related articles for article (PubMed ID: 34936380)
21. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
22. IL-2 receptor engineering enhances regulatory T cell function suppressed by calcineurin inhibitor.
Hirai T; Lin PY; Ramos TL; Simonetta F; Su LL; Picton LK; Baker J; Lohmeyer JK; Garcia KC; Negrin RS
Am J Transplant; 2022 Dec; 22(12):3061-3068. PubMed ID: 36031344
[TBL] [Abstract][Full Text] [Related]
23. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
Hoyos V; Savoldo B; Quintarelli C; Mahendravada A; Zhang M; Vera J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Leukemia; 2010 Jun; 24(6):1160-70. PubMed ID: 20428207
[TBL] [Abstract][Full Text] [Related]
24. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
[TBL] [Abstract][Full Text] [Related]
27. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
Front Immunol; 2020; 11():1347. PubMed ID: 32714329
[TBL] [Abstract][Full Text] [Related]
28. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
[TBL] [Abstract][Full Text] [Related]
29. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
30. Novel method for effectively amplifying human peripheral blood T cells in vitro.
Ye J; Cao W; Tao Z; Zhao S; Wang C; Xu X; Zhao A; Gao J
Exp Cell Res; 2021 Feb; 399(1):112451. PubMed ID: 33352191
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
32. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
Qin H; Cho M; Haso W; Zhang L; Tasian SK; Oo HZ; Negri GL; Lin Y; Zou J; Mallon BS; Maude S; Teachey DT; Barrett DM; Orentas RJ; Daugaard M; Sorensen PH; Grupp SA; Fry TJ
Blood; 2015 Jul; 126(5):629-39. PubMed ID: 26041741
[TBL] [Abstract][Full Text] [Related]
33. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
34. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.
Avanzi MP; Yeku O; Li X; Wijewarnasuriya DP; van Leeuwen DG; Cheung K; Park H; Purdon TJ; Daniyan AF; Spitzer MH; Brentjens RJ
Cell Rep; 2018 May; 23(7):2130-2141. PubMed ID: 29768210
[TBL] [Abstract][Full Text] [Related]
35. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
36. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy.
Hirayama AV; Chou CK; Miyazaki T; Steinmetz RN; Di HA; Fraessle SP; Gauthier J; Fiorenza S; Hawkins RM; Overwijk WW; Riddell SR; Marcondes MQ; Turtle CJ
Blood Adv; 2023 Jun; 7(11):2479-2493. PubMed ID: 36332004
[TBL] [Abstract][Full Text] [Related]
37. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
38. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG
EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863
[TBL] [Abstract][Full Text] [Related]
39. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
[TBL] [Abstract][Full Text] [Related]
40. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
